- Home
- DHT vs SNDX Comparison
DHT vs SNDX Comparison
Compare DHT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DHT | SNDX |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DHT | SNDX |
|---|---|---|
| Price | $15.48 | $21.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $16.33 | ★ $80.23 |
| AVG Volume (30 Days) | ★ 2.6M | 1.2M |
| Earning Date | 02-04-2026 | 03-02-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ 16.96 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $551,343,000.00 | $111,304,000.00 |
| Revenue This Year | N/A | $617.40 |
| Revenue Next Year | $5.16 | $115.70 |
| P/E Ratio | $11.50 | ★ N/A |
| Revenue Growth | N/A | ★ 595.65 |
| 52 Week Low | $9.00 | $8.58 |
| 52 Week High | $15.17 | $22.73 |
Technical Indicators
Market Signals| Indicator | DHT | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 77.03 | 57.86 |
| Support Level | $13.90 | $20.00 |
| Resistance Level | $14.49 | $22.00 |
| Average True Range (ATR) | 0.44 | 1.11 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 91.00 | 82.22 |
Price Performance
Historical ComparisonAbout DHT DHT Holdings Inc.
DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.